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Supplementation of omega-3 (n-3) and omega-6 (n-6) long-chain 
polyunsaturated fatty acids (LCPUFA) during the first year of life has been associated 
with a decreased incidence of illness in children.  The need to determine the most 
effective dose of n-3 and n-6 LCPUFA for infants and children remains, especially in 
regards to docosahexaenoic acid (DHA). 
This study was a double-blind, 2-phase, randomized, controlled, parallel-
group, prospective trial.  The primary outcome of the study was to evaluate whether 
DHA and ARA supplemented infant formula affected visual evoked potential acuity 
in term infants.  For the purposes of this thesis project, the outcome is illness as 
recorded through adverse events during the original study from birth to 4 years of 
age.  One-hundred and fifty-nine infants were randomized into 4 groups of which 91 
were eligible for medical record review.  Infants were given milk-based infant 
formula containing no DHA (control formula, n=19), 0.32% DHA (n=25), 0.64% 
DHA (n=19), or 0.96% of total fatty acids as DHA (n=28).  The study was controlled 
for ARA (0.64% of the total fatty acids) with a dose response to DHA – the control 
group received no DHA or ARA.   
Significantly fewer illnesses were seen in children supplemented with DHA 
and ARA when compared to the control during the first four years of life.  Subjects 
receiving the formula that contained 0.96% DHA from fatty acids were significantly 
less likely to be diagnosed with any illness during the first year of life (p = 0.01) 
when compared to the control group.  These subjects were also less likely to be 
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diagnosed with respiratory diagnoses (p = 0.05), any allergy diagnoses (p = 0.003), 
combined wheeze/asthma/skin diagnoses (p = 0.003), and skin allergic illnesses (p = 
0.02).  Additionally, the 0.64% DHA group experienced fewer ears, eyes, nose, and 
throat diagnoses (p = 0.05) during the first year of life. 
In conclusion, DHA and ARA supplementation of infant formula was 
associated with a reduced incidence of overall diagnoses, respiratory diagnoses, 
allergic diagnoses, skin diagnoses, combined wheeze/asthma/skin allergic diagnoses, 
as well as skin allergic illness diagnoses in children up to 4 years of age. 
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 Several previous studies have suggested that omega-3 polyunsaturated fatty 
acids cause a reduction of illness, such as infections, respiratory illness, asthma, and 
dermatologic conditions, in children (1-7).  Dietary fats, like omega-3 and omega-6 
fatty acids, play a role in regulating immune function and inflammation (8).  It is 
these functions that suggest the importance of long-chain polyunsaturated fatty acids 
(LCPUFA) in preventing and reducing illness in children.  While two previous 
studies have addressed this topic in infants(2,5), only one(2) used random assignment 
and that study was done in a higher socioeconomic population and provided only one 
level of formula LCPUFA in addition to the control.  The most similar study was the 
study conducted by Pastor et al (5).  In this study, 1,342 infants were enrolled, and the 
experimental group was given 17 mg DHA and 34 mg ARA per 100 kilocalories of 
formula.  Although this study had adequate power, the study was open-label, and thus 
the researchers were aware of the treatment assignment.    Also, the control group did 
not seem to truly be controlled, since those infants consumed formula containing 0 to 
16 mg DHA and 0 to 13 mg ARA.  The other studies relating to the effect of DHA 
and ARA consumption on illness(1-7) did not investigate the effect in infants from 
birth to 12 months, the effect of consumption of differing amounts of DHA with 34 
mg ARA, the effect on a greater variety of illnesses, or the effect on infants in the 
United States population.   
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Statement of Purpose 
 The purpose of this study is to determine if infants who consume DHA and 
ARA fortified formula are less likely to have reports of infections, asthma episodes, 
respiratory illnesses, and dermatologic conditions.  Additionally, I plan to determine 
the effect of dose of formula containing DHA and ARA on illness in infants from 
birth until 4 years of age.   
Research Questions 
 If an infant consumes infant formula fortified with DHA and ARA from birth 
to 12 months, will they be less likely to have episodes of illness such as 
infections, asthma, respiratory illnesses, and dermatologic conditions during 
the first 12 months of life when compared to the control group receiving no 
DHA or ARA? 
 If an infant consumes infant formula fortified with DHA and ARA from birth 
to 12 months, will they be less likely to have episodes of illness such as 
infections, asthma, respiratory illnesses, and dermatologic conditions during 
the first 4 years of life? 
 Will higher doses of DHA (0.64% or 0.96% fatty acids from DHA)with ARA 
intake consumed in infant formula cause fewer episodes of illness compared 
to lower doses of DHA (no DHA or 0.32% fatty acids from DHA) with ARA 
intake consumed from infant formula? 
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Chapter 2 
Review of Literature 
Docosahexaenoic acid (DHA; 22:6n-3) and arachidonic acid (ARA; 20:4n-6) 
are long-chain polyunsaturated fatty acids (LCPUFAs) that are consumed directly 
from the diet, or they can be produced by the body from α-linolenic acid (ALA; 
18:3n-3) and linoleic acid (LA; 18:2n-6), respectively (8).  Docosahexaenoic acid 
(DHA) is found in the membrane phospholipids of the retina and brain, and has been 
found to rapidly accumulate in these tissues during early infancy (9).  Specifically, 
DHA is found in high concentrations in the gray matter of brain tissue, and in the rod 
and cone outer segment membranes of the retina (10). The realization that high levels 
of DHA are found in these tissues and that DHA is found in human milk has led to 
the hypotheses that DHA is important for visual and neurological development for the 
developing fetus and during early infancy (9).  Visual acuity development has been 
studied frequently, but few studies have looked at indications of the developing 
immune system. 
DHA and Lactation 
DHA is found in human milk, and the amount varies greatly as a result of 
differing maternal diets.  DHA supplementation of lactating women has been found to 
increase breast milk DHA content (11).  Even though DHA can be produced by the 
body from its precursor, alpha-linolenic acid (ALA), supplementation of the precursor 
does not increase breast milk DHA content (12).  Genetics also play a role in the 
amount of DHA in breast milk and the human body.  Lactating women with the 347S 
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variant of the apolipoprotein A-IV gene have been shown to have about 40% more 
DHA in their milk compared to lactating women with the 347T variant (13). 
DHA Concentrations in Breast Milk 
As noted above, the DHA content of women‟s milk is influenced by factors 
including dietary intake and genetics (13,14). In a meta-analysis, Brenna et al. (14) 
analyzed 65 studies detailing the fatty acid composition of human breast milk to 
estimate average fatty acid profiles.  Analysis of the 65 studies involving 2474 
women gave a mean concentration of DHA in breast milk of 0.32% ± 0.22% of total 
fatty acids with a range of 0.06-1.4%.  The mean concentration of ARA was 0.47 
±0.13% of total fatty acids with a range of 0.24-1.0%.  These profiles and ranges 
showed that DHA was highly variable compared to ARA found in breast milk (14). 
Meneses et al. (15) studied the relationship between maternal age and milk 
DHA.  They asked if adolescents would have lower LCPUFA levels in breast milk, 
since adolescents typically have lower dietary intakes of LCPUFA when compared to 
adults. Among Brazilian adolescents aged 14-19 years, they found that there was no 
significant difference of individual LCPUFA in breast milk when compared to 
Brazilian adults of the same socioeconomic status.  This result was interesting since 
the adolescents‟ mean dietary intakes of n-3 and n-6 LCPUFA were lower when 
compared to the lactating adults.  The study did not provide data as to the dietary 
intake of specific LCPUFA, but the researchers did mention that there was a low 
intake of n-3 LCPUFA among the adolescents since only 10% reported a regular 
intake of fish and fish products.  The researchers theorized that the transfer of 
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essential fatty acids and LCPUFA to the mammary glands could take precedence over 
transfer to maternal tissues, and this is what could have caused the adolescent mothers 
to have breast milk with similar LCPUFA profiles when compared to adults with 
higher mean dietary intakes of n-3 and n-6 LCPUFA.  This was a cross-sectional 
study involving 30 Brazilian adolescents with a mean age of 16.6 years.  Inclusion 
criteria included a healthy full term singleton pregnancy, exclusively or 
predominately breastfeeding, and 2-6 years post menarche (mean of 5.0 years).  
„Predominately breastfeeding‟ was defined as breast feeding plus sparse use of water, 
tea/herbal infusions, and water diluted fruit juices.  Breast milk and blood samples 
were obtained between 30 and 120 days postpartum after an 11 hour fast. 
Multiple studies (11,13,15-17) have shown that DHA levels in breast milk can 
be increased through supplementation.  A study involving pregnant women in 
Western Australia found that breast milk from women who received fish oil contained 
higher amounts of DHA and eicosapentaenoic acid (EPA) when compared to controls 
at 3 days and 6 weeks after delivery (16).  This was a randomized controlled, double-
blind study involving 98 pregnant women who delivered after 36 weeks of gestation.  
The experimental group was given 4 fish oil capsules containing 2.2 g DHA and 1.1 g 
EPA, and the control group was given four 1 g olive oil capsules. 
In the Netherlands, a study found that breast milk ARA and DHA responded 
to maternal supplementation of these fatty acids, and that the amounts of ARA and 
DHA in breast milk declined with advancing lactation (17).  This study examined the 
influence of supplementation with ARA and DHA or DHA alone from early 
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pregnancy through 12 weeks of lactation on the composition of milk ARA, DHA, and 
the ratio of DHA:ARA.  One-hundred eighty-two women participated in the study of 
which 69 breastfed for at least 12 weeks.  DHA was more responsive to 
supplementation than ARA.  DHA supplementation resulted in decreased ARA in 
breast milk.   
Dietary Recommendations of DHA during Pregnancy and Infancy 
 There are currently no US Dietary Reference Intakes (DRI) for DHA.  In 
2002, the Food and Nutrition Board of the Institute of Medicine concluded that there 
was a lack of evidence for setting a DRI for n-3 or n-6 fatty acids.  Instead, they set 
Adequate Intakes (AI) based on dietary surveys measuring the median n-3 and n-6 
intakes in the United States (10).  The current recommended AI for n-3 fatty acids 
during pregnancy is 1.4 grams/day and 1.3 grams/day during lactation, and is linked 
to ALA intake rather than to DHA intake.  The AI for n-6 fatty acids is 13 grams/day 
during pregnancy and lactation, and is based on total n-6 fatty acids, primarily LA 
(18). 
Innis describes how estimates of requirements have typically been achieved in 
the past (10).  To estimate a requirement, the necessary information would include the 
knowledge of “the intake needed to maintain a given circulating level, tissue 
concentration, or adequacy of molecular function”, “the intake of individuals in 
groups, which are associated with the absence of any signs of deficiency”, “the intake 
needed to maintain balance, considering intake in relation to status”, and “studies of 
subjects maintained in diets containing low or deficient levels of a nutrient followed 
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by correction of a deficit when measured amounts of that nutrient are provided.” 
These criteria were used to set total n-3 and n-6 AIs. 
Interestingly, it was found by Schwartz et al. (19) that infants consuming 
present-day formula supplemented with LCPUFAs were able to achieve plasma 
LCPUFA concentrations similar to that of breastfed infants, but those receiving only 
ALA and LA were not.  In this study, the parents chose what formula they wanted to 
feed their infant, and the categories included breast milk, formula with no LCPUFAs, 
and formula with LCPUFAs.  They were instructed to fully milk feed (formula-feed 
or breastfeed) their infants until at least 4 months of age.   
An AI for DHA has not been set because at the time of the last review (10) in 
2002, functional effects of DHA supplements were not generally known.  This might 
not be the case today.    
Benefits of DHA from Breast Milk and Supplemented Infant Formula 
 Polyunsaturated fatty acids (PUFAs), including DHA, modulate gene 
expression, regulate the production of eicosanoids (that play a role in inflammation), 
and regulate the physical properties of cell membranes.  Because of these properties, 
PUFAs play a role in the prevention of neurological disorders and in the etiologies of 
chronic disease (20).  
 In a prospective cohort study investigating the relationship between DHA and 
neurophysical functioning, it was found that children who breastfed or were fed 
DHA-fortified formula for the first 6 months after birth had higher mean full-scale 
and verbal IQ scores at 4 years when compared to those who were fed mainly 
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unfortified formulas (21).   This study took place in Southampton, UK, and included 
241 children who were followed from birth to 4 years of age.  The researchers of this 
study did note that the differences in the children‟s IQ scores according to the type of 
formula that they were fed may be more due to confounding by maternal or family 
characteristics than to the amount of PUFAs they received in the formulas.  They 
determined that this difference could be explained by maternal education and 
intelligence.  The difference could also be explained by the increased cost of infant 
formula in comparison to the cost of breastfeeding as well as the increased cost of 
formulas supplemented with DHA. 
   Birch et al. (22) found that the supplementation of infant formula with DHA 
and ARA helps to support IQ and visual acuity at 4 years of age similar to that of 
infants who were breast-fed.  In their study, 79 infants were enrolled and were given 
infant formula supplemented with microalgal and microfungal DHA and ARA, 
respectively, for the first 17 weeks of life.  Of the 79 healthy term infants, 52 were 
available for testing at 4 years of age.  Additionally, 40 healthy term breast-fed 
infants were enrolled in the study for comparison, of which 32 were available for 
testing at 4 years of age.  The researchers also found that the children who were fed 
formula with no DHA or ARA had significantly lower visual acuity and verbal IQ 
scores in comparison to the children who were breast-fed for an average of 43 weeks.  
Immunity and Fatty Acid Intake 
During the immune response, organisms and substances that cause disease or 
invade our body are identified, attacked, and eliminated.  The immune cells used 
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during this response are produced in bone marrow and are then stored throughout the 
body.  When these cells enter the bloodstream, they are usually referred to as the 
white blood cells or leukocytes (8). 
There are 2 types of immunity, and these are known as innate and acquired.  
Innate immunity is the first line of defense against a foreign organism or substance in 
the body.  This type of immunity uses no memory of the foreign agent, and begins 
with the production of cytokines at the site of the infection and inflammation.  
Cytokines are specialized chemical mediators that in turn cause movement of immune 
cells to the injured site.  Specialized cells are then activated to identify and destroy 
bacteria, and remove dead cells and foreign substances (8). 
The presentation of antigens causes the activation of acquired immunity. 
Acquired immunity is specific and is developed throughout the human life.  It 
involves immunological memory and the help of T and B lymphocytes.  T 
lymphocytes are involved with the cell-mediated immune responses and B cells are 
involved with the humoral immune response.  This type of immunity is specific to the 
recognition of non-self antigens, which in turn allows tailored responses towards 
specific antigens or pathogen-infected cells (8).  
Autoimmunity is “the failure of an organism to recognize its own constituent 
parts as self, which results in an immune response against its own cells and tissues.”  




Dietary fats are known to play a role in regulating immune function and 
inflammation.  The functional roles of fatty acids are mostly due to the products of 
LA and ALA, the n-6 and n-3 LCPUFAs, respectively.  DHA and ARA are 
precursors to lipid mediators that play a role in the activation and resolution of the 
inflammatory process.  ARA is a precursor for eicosanoids that activate pro-
inflammatory mediators, and yet at the same time the eicosanoids produce lipoxins 
that activate anti-inflammatory mediators.  Docosanoids are made from DHA that 
produce resolvins and protectins to activate anti-inflammatory mediators.  Many of 
these mediators are involved in cell signaling processes leading to the activation or 
resolution of the inflammatory process (8).  
The anti- and pro-inflammatory properties of DHA and ARA have led to the 
research of their effect on illnesses that exhibit inflammatory processes.  Several 
previous studies (1-7) have suggested that n-3 polyunsaturated fatty acids cause a 
reduction of illness, such as infections, respiratory illness, asthma, and dermatologic 
conditions, in children.   
Illness in Children Supplemented with DHA 
Thienprasert et al. (3) conducted a placebo-controlled, randomized, double-
blind study and found that fish oil supplementation reduced illness in healthy 9 to 12-
year-old Thai schoolchildren.  The experimental group receiving the fish oil treatment 
consumed UHT (ultra heat treatment) chocolate milk that contained 200 mg EPA and 
1 g DHA in 2 g oil once a day, five times a week for 6 months. The control group 
consumed UHT chocolate milk containing 2 g of soybean oil.  Episodes and duration 
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of illness were recorded daily during the intervention period by research assistants.  
The types of illness identified and recorded included rhinitis, the common cold, 
influenza, and diarrhea.  The researchers found that supplementation of the chocolate 
milk with EPA and DHA was an effective method at increasing the blood status of 
the fatty acids in the children.  There was a significant difference (p < 0.012) when 
comparing fatty acid status before and after supplementation, as well as when 
comparing fatty acid status after supplementation between placebo and treatment 
groups (p < 0.001).  It was found that participants receiving the fish oil treatment 
were significantly less likely (p = 0.006) to become ill due to any of the recorded 
illnesses.  In particular, they tended to be less likely (p = 0.089) to have febrile 
illnesses.  Also, the duration of their illnesses was significantly shorter in the group 
receiving the fish oil (p = 0.014).   These findings suggest that the improvement in 
immune function, or more specifically, host defense could be due to the 
supplementation of the above mentioned fatty acids in the schoolchildren. 
In a study conducted at the University of Kansas Medical Center, researchers 
found that the incidence of illness was decreased in toddlers who were fed a DHA-
supplemented toddler formula for two months (1).  Children were randomly assigned 
to receive a cow-milk based toddler formula that contained 0 mg, 43 mg, or 130 mg 
DHA per 237 ml.  The parents were instructed to provide the study formula as a milk 
replacement for one meal each day for 60 consecutive days.  To determine the 
incidence of illness, medical records were collected at the end of the study, and 
parents were questioned at the 2nd and 3rd visit about the health of their child during 
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the previous month.  Among different classes of adverse events reported, an overall 
group difference (p = 0.024) was detected only in the number of participants 
experiencing one or more respiratory illnesses.  The participants receiving the 130 mg 
DHA supplemented formula experienced significantly fewer events of all illnesses (p 
= 0.007) than those receiving the control (0 mg DHA) formula. 
Respiratory Illness 
Pastor et al. (5) followed illness in 1,342 infants who were assigned to 
formulas with or without varying amounts of DHA and ARA.  They found that 
infants receiving DHA and ARA-enriched formula had fewer episodes of bronchitis 
and bronchiolitis.  The study while prospective was not blinded.  Three-hundred fifty-
seven pediatricians from different areas of Spain enrolled about 5 participants each.  
One-thousand ninety-four infants received 17 mg DHA and 34 mg ARA for every 
100 kilocalories of formula, and 248 infants received levels of DHA and ARA 
ranging from 0 to 16 mg DHA and 0 to 13 mg ARA per 100 kilocalories of formula.  
On average, the infants began their assigned formulas at about the age of 1 month.  
Infants fed lower DHA and ARA amounts had a greater incidence of 
bronchitis/bronchiolitis at 5 (13.9% compared to 6.1%), 7 (10.8% vs. 5.1%), and 9 
(11.3% vs. 5.8%) months of age.  Additionally, there were greater occurrences of 
rhinitis (p = 0.05) and upper respiratory infections (p = 0.05) at 1 month in the control 
group compared to the DHA treatment group.  At 12 months, a higher incidence of 
upper respiratory infections was also found in the control group (p = 0.01).   The 
results of this study support previous research of LCPUFA roles in protecting against 
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respiratory symptoms (1-3).  It was also noted by investigators (5) that the study 
design did not allow them to pinpoint whether the reason for the reduction in illness 
was due to a reduction of infection or inflammatory response. 
 In a recent study, DHA/ARA supplementation of infant formula was 
associated with a reduced incidence of upper respiratory infections, common allergic 
diseases, and wheezing or asthma in children up to 3 years of age (2).  Beginning at ≤ 
5 days until 12 months of age, infants consumed either a control formula (Enfamil 
with iron; Mead Johnson Nutrition, Evansville, Indiana), or a formula supplemented 
with DHA and ARA (Enfamil LIPIL; Mead Johnson Nutrition) containing 0.32% -
0.36% of total fatty acids as DHA and 0.64% - 0.72% of total fatty acids as ARA.  
Infants were recruited from two Dallas area hospitals, and all were singleton births 
born between 37 and 40 weeks of gestational age.    To be included in the study, the 
infants had to be healthy term infants and exclusively formula-fed.  The original 
objectives of the study were to evaluate the effect of DHA and ARA supplementation 
on visual cortex maturity, and to evaluate the effect of LCPUFA on metabolic 
parameters.  The objective of this study was to investigate the incidence of allergic 
manifestations and common respiratory illnesses in children using chart review.  The 
medical charts of the infants were reviewed by study nurses who were unaware of the 
infant‟s formula assignment.  The charts were reviewed for diagnoses of upper 
respiratory infection, wheezing, asthma, reactive airway disease, 
bronchiolitis/bronchitis, pneumonia, allergic rhinitis, allergic conjunctivitis, otitis 
media, sinusitis, food allergy, atopic dermatitis, urticaria, and drug allergy.  The 
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medical records of 89 infants were reviewed, of which 51 received the control 
formula and 38 received the DHA/ARA supplemented formula. 
Asthma and Allergies 
A descriptive cross-sectional study found that children aged 8-11 years who 
regularly consumed fresh, oily fish had a decreased risk (odds ratio of 0.26) of current 
asthma compared to children who did not regularly consume fresh, oily fish (7).  
Asthma was defined as recent wheeze and airway hyperresponsiveness (AHR) to 
exercise.  Parents of the children completed a questionnaire on occurrence of asthma 
or wheeze in the previous 12 months, and a food frequency questionnaire that 
provided information on their fish intake.  Eight hundred and eight children were 
randomly selected from schools in Sydney, Australia, and 468 families completed the 
questionnaires.  
In a study conducted by Hwang et al. (4), it was found that the amounts of red 
blood cell (RBC) n-3 PUFA, including EPA and DHA, were significantly lower in 
preschoolers who had atopic dermatitis, allergic rhinitis, and asthma than those 
without atopic illnesses.  The preschoolers with atopy also had significantly higher n-
6 PUFA, particularly ARA.  The researchers concluded that the n-3 PUFA of the 
RBC membrane could be a marker for risk of atopy in early childhood, and that fatty 
acid disturbances may be an indicator of risk for early childhood atopic diseases.  
This study included 497 children aged 4-6 years from Pusan, South Korea.  Twenty-
nine percent of the children had atopic disease including atopic dermatitis, allergic 
rhinitis, and asthma. 
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N-3 LCPUFA are anti-inflammatory (8).  At least one study (6) found that n-3 
LCPUFA from fish oil was effective for the treatment of asthma symptoms.  
Nagakura et al. (6) found that dietary supplementation with fish oil in children was 
beneficial for children with bronchial asthma in a strictly controlled environment (6).  
The study was double-blind, randomized, and controlled.  For the first 2 months, the 
children were observed and data were recorded.  For the next 10 months, fish oil was 
administered.  During the administration period, 30 children 4-17 years of age were 
given fish oil capsules (300 mg) containing 34 mg EPA and 36 mg DHA or a placebo 
of 300 mg olive oil.  The children were instructed to take 6-12 capsules/day 
depending on their weight.  This gave a daily range of 17.0-26.8 mg/kg of EPA, and 
7.3-11.5 mg/kg DHA.  An acetylcholine inhalation test was administered to the 
children, to test for responsiveness to acetylcholine.  The researchers found that 
asthma symptom scores were decreased and the responsiveness to acetylcholine was 
decreased in the fish oil group when compared to the control group. 
Behavior and Neurodevelopment 
In an open-label, proof-of-efficacy pilot study, researchers investigated the 
effect of high-dose EPA/DHA supplementation on behavior in children with ADHD 
(23).  They found that the supplementation of EPA and DHA led to significant 
increases in EPA and DHA, and significant decreases in the ARA:EPA ratio.  
Additionally, significant improvements in behavior were noted with respect to 
inattention, hyperactivity, oppositional/defiant behavior, and conduct disorder.  This 
pilot study included 9 children in Sudbury, MA who were originally given 2 
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tablespoons of a liquid EPA/DHA supplement containing 10.8 g EPA and 5.4 g DHA 
per day.  At 4 weeks, the dose of the EPA/DHA supplements was adjusted depending 
on the ratio of ARA to EPA in the plasma phospholipids to increase the likelihood 
that the subjects would reach a level normally found in the Japanese population.  The 
goal was to reach an ARA:EPA ratio between 1.5 and 3. 
In a meta-analysis by Beyerlein et al. (24), no significant difference in Bayley 
mental scales or psychomotor developmental indexes were found at 18-months in 
toddlers given a formula supplemented with LCPUFAs as infants compared to those 
fed a control formula with no LCPUFAs.  The LCPUFA-supplemented formulas 
contained 0.17-0.5 g DHA and 0.04-0.4 g ARA per 100 g fat.  The analysis included 
data from 870 children from 4 large randomized clinical trials in which children were 
given infant formula with or without LCPUFAs.   
Summary 
 Several previous studies have shown a reduction of illness in children 
supplemented with DHA during infancy.  However, the need remains to determine 
the effect of consumption of differing amounts of DHA with a controlled amount of 
ARA, the effect on a greater variety of illnesses, and the effect on infants in the 
United States population.  The ability to answer these questions would aid the Food 
and Nutrition Board of the Institute of Medicine in determining the appropriate DRI 







This was a double-blind, 2-phase, randomized, controlled, parallel-group, 
prospective trial.  The primary outcome of the study was to evaluate whether DHA 
and ARA supplemented infant formula affected visual evoked potential acuity in term 
infants.  For the purposes of my thesis research, the outcome is illness as recorded 
through adverse events during the study.  An adverse event is defined as “any 
unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom or disease temporally associated with the participation in a clinical study 
whether or not related to study product.”  Adverse events were recorded from 7 days 
of age to 4 years of age.   
Ethics 
This study was conducted in accordance with the ethical principles of the 
Declaration of Helsinki.  The protocol, amendments and informed consent were 
reviewed and approved by the Institutional Review Board Ethics Committee and the 
Human Subjects Committee of the University of Kansas Medical Center in Kansas 
City, KS.  Written informed consent was obtained for every participant from his/her 
parent or guardian prior to participation in the clinical trial.  
Subject Selection 
To be included in this study, participants (the infant) had to meet the 
following inclusion criteria: singleton birth, 37 – 42 weeks gestational age, birth 
weight 2490 to 4200g, five to nine days of age at randomization, and solely formula 
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fed for at least 24 hours prior to randomization.  Participants were excluded from the 
study if they had a history of underlying disease or congenital malformation which 
was likely to interfere with the normal growth and development of the participant.  
Other exclusion criteria included chronic illness of the mother likely to influence the 
growth and development of the participant, if the infant was breast-fed within 24 
hours prior to randomization, and any evidence of formula intolerance or poor intake 
of formula at the time of randomization.     
Women who had stated that they had planned to feed infant formula to their 
newborn were approached for recruitment on the day they were expected to deliver.  
If they expressed interest in allowing their child to enroll in the study and met the 
inclusion criteria and none of the exclusion criteria, they were contacted after birth 
and the study was explained thoroughly.  Written informed consent was collected if 
the mother decided to participate in the study. 
Randomization 
The infants were randomized into 4 groups and were given milk-based infant 
formula containing no DHA (control formula), 0.32% DHA, 0.64% DHA, or 0.96% 
of total fatty acids as DHA.  The study was controlled for ARA (0.64% of the total 
fatty acids) with a dose response to DHA – the control group received no DHA or 
ARA.  The DHA was from an algal source and the ARA was from a fungal source.  
The formula was consumed from birth until 12 months of age, and the mother was 




Blood samples measuring DHA and ARA in erythrocyte membranes were 
taken at 4 months and 12 months.  When available, cord blood was also analyzed at 
birth.  Episodes of illness and the length of illness were recorded based on medical 
doctor visits and caretaker reports. To obtain medical records, consent was obtained 
from the parent giving permission to request medical records from any hospital or 
clinic a child had attended (See Appendix B).  Medical record requests were faxed 
once a year to all reported hospitals and clinics attended by the child around the time 
of each child‟s birthday.  At each visit, the caretaker was asked whether their child 
had been sick or not acting well since his/her last visit (See Appendix C).  Whether 
the child was treated at home or by a doctor was recorded, as well as any treatment or 
medication the child had received.  Additionally, parent reports of a doctor visit were 
verified with medical records requested by the study research assistants.  Adverse 
events were recorded from 42 ± 7 days of age until 4 years ± 7 days of age at each 
study visit.  Visits were at 7-9 days, 6 weeks, 4, 6, 9, 10, 12, and then every 6 months 
until 4 years of age of the infant.   Adverse events were recorded and coded using 
codes under the following categories: body as a whole (i.e. irritability); eyes, ears, 
nose, throat (i.e. otitis media); gastrointestinal (i.e. diarrhea); metabolic and nutrition 
(i.e. weight loss); nervous system (i.e. seizure/convulsion); respiratory (i.e. upper 
respiratory infection); skin (i.e. diaper rash); urogenital (i.e. urinary tract infection); 
and other.  See Appendix F for more details on adverse event codes.  Consecutive 
illnesses were considered separate if they occurred greater than 28 days of each other, 
28 
except for allergic diagnoses (any allergy diagnoses) that were considered separate 
diagnoses after 7 days of duration.  Adverse events were then grouped into categories 
for comparison and statistical analysis (See Appendix E).  
Subjects 
 A total of 159 subjects participated in the original DHA study, of which 91 
children had adequate medical records and were eligible for medical record review.  
A medical record was considered adequate if the subject had not dropped from the 
current follow-up study.  Additionally, medical records of dropped subjects were 
reviewed if the age of the child at the last medical record received was at least 3 years 
or greater.  As seen in Figure 1, there were 19 participants in the control group, 25 
participants in the 0.32% DHA group, 19 participants in the 0.64% DHA group, and 
28 participants in the 0.96% DHA group that were eligible for medical record review.     
 




Characteristics of the study population were analyzed using the Chi-squared 
test and ANOVA, reported as n (%) and mean ± standard deviation, respectively.  
The incidence of illness was calculated using Chi-squared comparing the combined 
treatment groups to the control group.  Statistical differences found between the 
average number of illnesses per child was calculated using an equal variance T-test 
comparing each of the treatment groups to the control group.  Odds ratio was 
calculated using the Fisher exact probability test.  Results were considered significant 






There were no significant differences among the characteristics of the study 
subjects, as shown in Table 1. 











Male* 8 (42%) 10 (40%) 6 (32%) 12 (43%) 0.88 
Hispanic* 0 (0%) 2 (8%) 0 (0%) 3 (11%) 0.13 
Caucasian* 2 (11%) 8 (32%) 7 (37%) 7 (25%) 0.13 
Birth weight, g** 3375±384 3522±370 3364±317 3380±363 0.387 
Birth length, cm** 49.7±1.82 50.5±1.86 50.1±1.84 50.2±1.56 0.516 
Weight at 1 year, g* 9587±1090 10052±1132 9671±1200 10107±1192 0.331 
Length at 1 year, cm** 75.0±2.93 75.7±3.30 75.9±3.46 75±2.25 0.787 
Maternal education in 
years** 
12.4±2.59 12.6±1.48 12.2±1.50 12.6±2.31 0.892 
Paternal education in 
years** 
11.8±1.81 12.3±1.44 12.3±1.67 11.7±1.55 0.560 
Maternal allergies 
reported* 
8 (42%) 8 (32%) 5 (26%) 12 (43%) 0.615 
Yes to smoking by anyone 
in the household* 
9 (47%) 9 (36%) 8 (42%) 8 (29%) 0.648 
Pack years smoked by 
mother** 
1.57±2.41 3.03±4.80 2.49±4.23 1.14±2.20 0.244 
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Greatest PPD smoked by 
household** 
0.33±0.50 0.51±0.84 0.52±0.65 0.35±0.70 0.772 
Yes to daycare in early life 
(between 3.5 to 5.5 yrs)* 
11 (58%) 9 (36%) 11 (58%) 15 (54%) 0.809 
Greatest number of 
children <13 years in 
home** 
2.9±1.08 3.3±1.21 2.8±1.54 2.9±1.10 0.561 
Yes to pets in the home* 6 (32%) 7 (28%) 8 (42%) 6 (21%) 0.493 
Greatest number of furred 
pets** 
0.47±0.800 0.53±0.717 0.81±1.109 0.30±0.559 0.282 
*Reported as n (%); χ2 test 
**Reported as mean ± standard deviation; ANOVA 
  
Incidence of Illness 
 When comparing the incidence of illness between the control group and the 
combined DHA and ARA treatment groups, significant differences were only found 
during the first year of life (Table 2).  In the control group, there was a greater 
incidence of skin allergic illness (p = 0.041), combined wheeze/asthma/skin 
diagnoses (p = 0.038), and any allergy diagnoses (p = 0.033).  Between 1 and 4 years 
of age, illnesses in children in the control group did not differ from illnesses in the 



















Any Diagnosis 19 100% 25 100% 18 95% 28 100% 0.605 
EENT Diagnosis 14 74% 21 84% 18 95% 22 79% 0.261 
GI Diagnosis 13 68% 18 72% 11 58% 12 43% 0.365 
GI Illness 5 26% 9 36% 6 32% 4 14% 0.995 
RESP Diagnosis 18 95% 20 80% 16 84% 21 75% 0.113 
Skin Diagnosis 17 90% 14 56% 16 84% 20 71% 0.078 
Urogenital Diagnosis 2 11% 1 4% 2 11% 1 4% 0.437 
URI  13 68% 18 72% 13 68% 17 61% 0.885 
Nonallergic Respiratory 
Illnesses 
16 84% 22 88% 15 79% 22 79% 0.817 
Wheeze/Asthma 5 26% 5 20% 2 11% 2 7% 0.138 
Skin Allergic Illness 9 47% 4 16% 6 32% 7 25% 0.041 
Wheeze/Asthma/Skin 11 58% 9 36% 7 37% 7 25% 0.038 
Any Allergy 12 63% 10 40% 8 42% 8 29% 0.033 
OM 10 53% 13 52% 9 47% 11 39% 0.598 
Respiratory Infectious 
Illness 
15 79% 18 72% 13 68% 19 68% 0.415 




















Any Diagnosis 17 90% 24 96% 17 90% 26 93% 0.602 
EENT Diagnosis 10 53% 15 60% 15 79% 17 61% 0.331 
GI Diagnosis 7 37% 12 48% 8 42% 11 39% 0.625 
GI Illness 3 16% 8 32% 4 21% 4 14% 0.539 
RESP Diagnosis 14 74% 18 72% 15 79% 17 61% 0.719 
Skin Diagnosis 14 74% 16 64% 14 74% 15 54% 0.364 
Urogenital Diagnosis 0 0% 1 4% 2 11% 3 11% 0.193 
URI  9 47% 14 56% 12 63% 13 46% 0.598 
Nonallergic Respiratory 
Illnesses 
13 68% 19 76% 15 79% 18 64% 0.744 
Wheeze/Asthma 6 32% 7 28% 7 37% 5 18% 0.652 
Skin Allergic Illness 8 42% 5 20% 7 37% 7 25% 0.182 
Wheeze/Asthma/Skin 9 47% 11 44% 10 53% 11 39% 0.820 
Any Allergy 10 53% 14 56% 11 58% 13 46% 0.991 
OM 8 42% 12 48% 9 47% 10 36% 0.941 
Respiratory Infectious 
Illness 
12 63% 15 60% 14 74% 14 50% 0.785 






















Any Diagnosis 19 100% 25 100% 18 95% 28 100% 0.605 
EENT Diagnosis 16 84% 22 88% 18 95% 27 96% 0.226 
GI Diagnosis 16 84% 21 84% 13 68% 19 68% 0.337 
GI Illness 8 42% 13 52% 9 47% 7 25% 0.885 
RESP Diagnosis 19 100% 22 88% 16 84.2% 26 93% 0.128 
Skin Diagnosis 19 100% 21 84% 18 95% 23 82% 0.085 
Urogenital Diagnosis 2 11% 2 8% 4 21% 4 14% 0.700 
URI  14 74% 21 84% 16 84% 23 82% 0.337 
Nonallergic Respiratory 
Illnesses 
18 95% 23 92% 17 89% 26 93% 0.655 
Wheeze/Asthma 8 42% 8 32% 7 37% 6 21% 0.282 
Skin Allergic Illness 12 63% 8 32% 10 53% 12 43% 0.095 
Wheeze/Asthma/Skin 13 68% 14 56% 13 68% 14 50% 0.365 
Any Allergy 14 74% 17 68% 14 74% 15 54% 0.423 
OM 13 68% 18 72% 13 68% 16 57% 0.797 
Respiratory Infectious 
Illness 
17 89% 21 84% 16 84% 24 86% 0.599 








Average Number of Illnesses per Child 
 Subjects receiving the formula that contained 0.96% DHA from fatty acids 
were significantly less likely to be diagnosed with any illness during the first year of 
life (p = 0.01) when compared to the control group.  These subjects were also less 
likely to be diagnosed with respiratory diagnoses (p = 0.05), any allergy diagnoses (p 
= 0.003), combined wheeze/asthma/skin diagnoses (p = 0.003), and skin allergic 
illnesses (p = 0.02).  Moreover, there was a trend toward less GI diagnoses (p = 0.06) 
and wheeze/asthma (p = 0.06) in the group receiving 0.96% DHA compared to the 
control group.  Skin diagnoses did not reach significance, but trended lower in all 
three supplemental groups compared to controls (p = 0.06, 0.09, 0.11, respectively, 
for the groups receiving 0.32, 0.64, and 0.96% DHA).  Skin allergic illness, which 
reached significance in infants fed the highest amount of DHA, trended lower 
(compared to controls) in both other supplement groups (0.32%, p = 0.11; 0.64%, p = 
0.13).  Similarly, any allergy and wheeze/asthma/skin trended lower in the 0.64% 
DHA group compared to the control group (p = 0.08 and p = 0.10, respectively). The 
0.64% DHA group experienced more ears, eyes, nose, and throat diagnoses (p = 0.05) 
during the first year of life compared to the control group.  These results are shown in 
Tables 5 – 7. 
 From 12 to 48 months of life, the only decrease in diagnoses was seen in the 
reduction of skin diagnoses among the 0.96% DHA group (p = 0.03). 
During the first four years of life (Table 7), significantly fewer illnesses were 
seen in the treatment group receiving 0.96% DHA.  The subjects in this group 
36 
experienced fewer episodes of skin diagnoses (p = 0.02), any allergy diagnoses (p = 
0.02), combined wheeze/asthma/skin diagnoses (p = 0.01), skin allergic illness 
diagnoses (p = 0.03), as well as fewer illness diagnoses overall (Any Diagnosis, p = 
0.03).   
 















































































































































































































































































































Table 7. Average number of illnesses per child (± standard deviation) during the first four 





















































































































































Odds Ratio of having at Least One Diagnosis or Illness 
 The odds ratio of having at least one diagnosis or illness is shown in Tables 8 
– 10.  Significant values were found only in the first year of life.  The 0.32% DHA 
group was less likely to have at least one skin diagnosis (p = 0.02) or skin allergic 
illness (p = 0.04).  Additionally, the 0.96% DHA group was found to be less likely to 
experience at least one allergy diagnosis (Any Allergy, p = 0.03) or combined 
wheeze/asthma/skin diagnosis (p = 0.03).  Overall, there appeared to be smaller odds 
of respiratory illness, skin illness, urogenital illness, any allergy, wheeze/asthma/skin, 
skin allergic illness, and respiratory infectious illness in all supplemental groups in 
the first year of life, but they did not reach statistical significance largely due to the 
low power of the study. 
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Table 8. OR (including 95% confidence interval) of having at least one diagnosis or illness 





P Value 0.64% 
DHA 
(n=19) 






























































































































Table 9. OR (including 95% confidence interval) of having at least one diagnosis or illness 





P Value 0.64% 
DHA 
(n=19) 






























































































































Table 10. OR (including 95% confidence interval) of having at least one diagnosis or illness 



































RESP Diagnosis 0 0.25 0 0.23 0 0.51 


























































































The results of this study show that children who were given DHA and ARA 
supplemented formula during the first year of life were significantly less likely to be 
diagnosed with illness during the first four years of life.  Specifically, there was a 
reduced number of overall diagnoses, respiratory diagnoses, allergic diagnoses, skin 
diagnoses, combined wheeze/asthma/skin allergic diagnoses, as well as skin allergic 
illness diagnoses in the 0.96% DHA group.  The 0.32% DHA group also experienced 
a reduction of skin diagnoses and skin allergic illnesses.  There seemed to be a greater 
reduction of illness in the 0.96% DHA group compared to the other two treatment 
groups based on the fact that they were more likely to show a significant decrease in 
incidence.  All supplemented groups trended lower on odds ratio data. 
Previous studies have suggested that the supplementation of 0.32% DHA and 
0.64% ARA during infancy leads to a significant reduction of upper respiratory 
infections, asthma, allergies, and atopic dermatitis (1-7).  The results from this study 
align with previous studies that found a reduction in allergies, and atopic dermatitis.  
However, the results from this study did not find a significant reduction of upper 
respiratory infections or asthma during the first four years of life. 
A DRI for DHA has yet to be set by the Food and Nutrition Board of the 
Institute of Medicine due to a lack of evidence on the topic (10,18).  Since the results 
of this study found a significant decrease of illness in the group receiving 0.96% 
DHA from fatty acids, these results could contribute to a recommendation for DHA 
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supplementation for infants and children.  However, more studies on this topic would 
be necessary to be able to determine a DRI for DHA during infancy.  Future double-
blind, randomized, controlled studies need to examine illness using a broader range of 
DHA supplementation in children.   
Illnesses were collected during the first 12 months as part of adverse event 
monitoring.  However, we did not hypothesize lower illness rates.  We continued to 
obtain medical records during our continued follow-up of this cohort, because data 
were emerging to suggest benefits for less respiratory illness and allergy (1-7). 
A limitation of this study is that illness was not a primary hypothesized 
outcome of the original study.  The original double-blind, 2-phase, randomized, 
controlled, parallel-group, prospective trial was designed to measure visual acuity and 
cognitive development in children up to 6 years of age.  Another limitation of this 
study is that parents did not report all hospitals or clinics to which they took their 
children for treatment.  Additionally, parents may not have taken their children to the 
doctor for all illnesses.  They might have been more likely to forget to report those 
occurrences of illness, particularly in years 1- 4 when they were seen in our follow-up 
at 6 month intervals (compared to about 2 month intervals in the first year of life).  
Another limitation is that during analysis, the skew was not checked.  Outliers could 
possibly account for the increase in illness in the 0.64% DHA group.  More accurate 
results would be achieved by accounting for any outliers.  
 In conclusion, the results of this study support the hypothesis that the 
supplementation of DHA and ARA from birth to 12 months reduces the occurrence of 
51 
illness, specifically respiratory diagnoses, skin diagnoses and skin allergic diagnoses.  
The results did not support the hypothesis that supplementation would decrease the 
incidence of upper respiratory infections or asthma.  Subjects that were given 0.96% 
of fatty acids from DHA seemed to have a decreased incidence of illness as evidenced 
by the greater amount of significant differences compared to the control.  The other 
two treatment groups did not yield as many significant differences when compared to 










 Dietary fats, like omega-3 and omega-6 fatty acids, play a role in regulating 
immune function and inflammation (8).  It is these functions that suggest the 
importance of long-chain polyunsaturated fatty acids (LCPUFA) in preventing and 
reducing illness in children. 
This study was a double-blind, 2-phase, randomized, controlled, parallel-
group, prospective trial.  The primary outcome of the study was to evaluate whether 
DHA and ARA supplemented infant formula affected visual evoked potential acuity 
in term infants.  For the purposes of this thesis project, the outcome was illness as 
recorded through adverse events during the original study.  The infants were 
randomized into 4 groups and were given milk-based infant formula containing no 
DHA (control formula), 0.32% DHA, 0.64% DHA, or 0.96% of total fatty acids as 
DHA.  The study was controlled for ARA (0.64% of the total fatty acids) with a dose 
response to DHA – the control group received no DHA or ARA. 
Children who were given formula supplemented with DHA and ARA had a 
reduced incidence of illness.  In particular, children supplemented with 0.96% of fatty 
acids from DHA experienced fewer episodes of respiratory diagnoses, allergy 
diagnoses, and allergic skin illnesses (atopic dermatitis, contact dermatitis, eczema, 
and urticaria).   
The results of this study could potentially aid the Food and Nutrition Board of 
the Institute of Medicine in setting a DRI for n-3 and n-6 fatty acids.  However, more 
53 
studies on this topic would be necessary to be able to determine a DRI for DHA and 
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Diagnosis Adverse Events Included 
Any Diagnosis  All diagnoses relating to illness (no accident or 
trauma adverse event codes included) 
Eyes, Ears, Nose, Throat (EENT) 
Diagnosis 
 Conjunctivitis 
 Ear Wax Excessive 
 Eye Movement Disorder 
 Infectious Conjunctivitis 
 Infectious Rhinitis 
 Infectious Sinusitis 
 Nasal Congestion 
 Nasal/Tear Duct Obstruction 
 Otitis Media 
 Purulent Rhinitis 
 Retinal Detachment/Hemorrhage 
 Rhinorrhea 
 Thrush 
 Watery Eye 
Gastrointestinal (GI) Diagnosis  Acute Gastroenteritis 
 Anal Fissure 





 G.E. Reflux 
 Rotavirus 
 Stomatitis 
 Umbilical Hernia 
Respiratory (RESP) Diagnosis  Bronchiolitis 
 Bronchitis 
 Cough 




 Respiratory Distress Syndrome 
 Respiratory Syncytial Virus 





Skin (SK) Diagnosis  Bacterial Skin Infection 
 Chicken Pox 
 Diaper Rash 
 Dry Skin 
 Erythema 
 Fungal Skin Infection 
 Hemangioma 
 Impetigo 
 Inclusion Cyst 
 Infection 
 Neonatal Acne 
 Nevus 
 Other Rash 
 Parasitic Skin Infection 
 Seborrhea 
 Staph Infection 
 Viral Skin Infection 
 Wart 
 Yeast Infection 
Urogenital (UG) Diagnosis  Abnormal Urine 
 Inguinal Hernia 
 Labial Adhesions 
 Penile Adhesions 
 Undescended Testes 
 Urinary Tract Infection 
 Vaginal Discharge 
 Vulvitis/Vaginitis 
Upper Respiratory Infections (URI)  URI alone 
Otitis Media (OM)  OM alone 
Any Allergy  Allergic Conjunctivitis 
 Allergic Cough (allergy medication given) 
 Allergic Rhinitis 
 Allergic Sinusitis 
 Allergy 
 Asthma 
 Atopic Dermatitis 
 Contact Dermatitis 
 Croup 
 Drug Allergy 
 Eczema 
 Food Allergy 
 Urticaria 
 Wheezing 
Wheeze/Asthma  Asthma 
 Wheezing 
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Wheeze/Asthma/Skin  Asthma 
 Atopic Dermatitis 




Skin Allergic Illness  Atopic Dermatitis 
 Contact Dermatitis 
 Eczema 
 Urticaria 










 Respiratory Syncytial Virus 
 Strep Throat 
 URI 
Gastrointestinal Illness  Acute Gastroenteritis 
 G.E. Reflux 























Adverse Event Codes 
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